The future of anti-CD20 monoclonal antibodies: are we making progress?

Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats

(2014) T. Tawara et al.   JOURNAL OF IMMUNOLOGY

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

Effect of FCGR2A and FCGR3A variants on CLL outcome

(2010) D. Dornan et al.   BLOOD

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

(2010) S. M. Jaglowski et al.   BLOOD

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling

(2010) S. de Haij et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2–Beclin1 interaction at endoplasmic reticulum

(2010) J Lian et al.   CELL DEATH AND DIFFERENTIATION

Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance

(2010) Laura Bonapace et al.   JOURNAL OF CLINICAL INVESTIGATION

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Investigational Immunotherapeutics for B-Cell Malignancies

(2010) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

When is a predose a dose too much?

(2009) T. Illidge et al.   BLOOD

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

(2009) J. Hiraga et al.   BLOOD

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions

(2009) M. I. Vega et al.   CLINICAL CANCER RESEARCH

Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils

(2009) Mami Shibata-Koyama et al.   EXPERIMENTAL HEMATOLOGY

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

(2009) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

(2009) Ellen J. Schlette et al.   LEUKEMIA & LYMPHOMA

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

(2008) D. M. Goldenberg et al.   BLOOD

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

(2008) F. T. Awan et al.   BLOOD

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

(2008) C. Stolz et al.   BLOOD

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV

(2008) V. Minard-Colin et al.   BLOOD

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis

(2008) A. Ivanov et al.   CLINICAL CANCER RESEARCH

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

(2008) E. Racila et al.   CLINICAL CANCER RESEARCH

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers

(2008) Wyndham H. Wilson et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

(2007) Danielle Canioni et al.   JOURNAL OF CLINICAL ONCOLOGY